Cashel Neural

Cashel Neural is a preclinical-stage biotechnology company spun out of the Cleveland Clinic to develop and commercialize novel therapies for multiple sclerosis (MS) and other neurodegenerative diseases. The company's research focuses on identifying and developing small molecules that promote remyelination by stimulating oligodendrocyte progenitor cells (OPCs) to differentiate into mature, myelinating oligodendrocytes. Its lead candidate, CN045, is a central nervous system (CNS)-penetrable small molecule that has demonstrated significant potency in promoting OPC differentiation and enhancing remyelination in preclinical models of demyelination. Cashel Neural aims to address the critical unmet need for therapies that repair myelin damage and prevent long-term neurodegeneration in MS patients.